若生智能
Drug Database
MF

MF-59 (MF59)

✓ Approved

Novartis AG · 小分子 · 小分子

什么是 MF-59？

MF-59 是一种小分子，由Novartis AG研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)。

药物档案

商品名MF59
公司Novartis AG
药物类别小分子
给药途径Injectable (Others)
状态Approved
来源： ClinicalTrials.gov, Novartis AG

治疗适应症

MF-59 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresOral appliance application✓ Approved

相关研究文献

PubMedJournal of vitreoretinal diseases2026-07-27

Correlation Between Multifocal Electroretinogram and Optical Coherence Tomography Findings With Visual Acuity in Patients With Macular Dystrophy.

Hassan Asmaa A, Abdel-Radi Mahmoud M, Aly Mohamed Omar M MOM, Saleh Mennatallah G A MGA et al.

To correlate the optical coherence tomography (OCT) findings and multifocal electroretinogram (mf-ERG) responses with visual acuity (VA) in patients with macular dystrophies. A cross-sectional study including 62 eyes of 31 patients diagnosed with macular dystrophy was conducted. All participants underwent assessment of corrected-distance VA, mf-ERG responses (data analysis were restricted to ring 1), and OCT parameters, including central macular thickness (CMT) and the integrity of the inner segment/outer segment (IS/OS) junction. The correlations between VA with mf-ERG responses and OCT parameters were analyzed. A statistically significant moderate correlation was found between corrected-distance VA and CMT (r = 0.497, P < .001), the mf-ERG amplitudes of N1 (r = 0.469, P < .001), N2 (r = 0.517, P < .001), and P1 (r = 0.494, P < .001), the mf-ERG latencies of N2 (r = -0.301, P = .017), and the integrity of the IS/OS junction (r = -480, P < .001). There was a statistically significant weak negative correlation between corrected-distance VA of the studied eyes with mf-ERG latencies of N1 (r = -0.269, P = .034) and P2 (r = -0.283, P = .026). Regression analysis showed that CMT and IS/OS junction integrity were the most significant predictors of VA, alongside mf-ERG amplitudes and latencies. CMT and the integrity of the IS/OS junction are strong structural indicators for visual function in patients with macular dystrophies. Moreover, mf-ERG is considered to play a crucial role in identifying early functional impairment before irreversible anatomic changes occur.

PMID 42504172
阅读全文 →
PubMedACS applied materials & interfaces2026-07-27

High-Throughput Compressed-Flux Growth of Perovskite Quantum Dot Films via Modular Precursor Feeding.

Chu Yongze Y, Liu Jingjing J, Jiang Jinke J, Wang Yuqi Y et al.

Translating metal halide perovskites from lab curiosity to commercial deployment requires high-throughput fabrication of stable, integration-ready material forms. This work reports a modular precursor feeding-integrated compressed-flux growth (MF-CFG) strategy for high-throughput fabrication and screening of perovskite quantum-dot-polymer composites. MF-CFG offers two key advantages: (1) it decouples precursor mixing from nucleation/growth within a confined hot-pressing flux, yielding nearly monodisperse quantum dots (∼5.5 nm, size deviation <10%) uniformly dispersed in a polymer matrix; and (2) by leveraging a library of standardized precursor modules and a combinatorial feeding strategy, it enables high-throughput composition-property mapping across diverse loading concentrations, A/B/X stoichiometries, halide and B-site alloying, and cross-family systems. The resulting MF-CFG perovskite quantum dot-doped polymer films exhibit enhanced photoluminescence, transparency, and X-ray response, alongside improved environmental resilience. As a proof of concept, MF-CFG CsPbBr3/PE films employed as color converters in white light-emitting diodes and as scintillator screens deliver wide-color-gamut emission (126% NTSC) and high-fidelity X-ray imaging (18 lp mm-1 spatial resolution at MTF = 0.2), resolving features down to ∼40 μm. MF-CFG therefore provides a scalable and generalizable platform that unites high-throughput material mapping with device-ready manufacture, accelerating translation of perovskite composites toward real-world applications.

PMID 42504450
阅读全文 →
PubMedJAMA pediatrics2026-07-27

Treatment of Multifood Allergy With Omalizumab or Multiallergen Oral Immunotherapy: A Randomized Clinical Trial.

Wood Robert A RA, Togias Alkis A, Burk Caitlin M CM, Sindher Sayantani S et al.

Food allergy is common, affecting up to 8% to 10% of children and adults. Treatment options include oral immunotherapy (OIT) and omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody. To compare omalizumab with OIT for the treatment of patients with multifood allergy. This was a double-blind, placebo-controlled, randomized clinical trial comparing omalizumab with omalizumab-facilitated multiallergen OIT (MOIT) in participants who completed stage 1 of the Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults With Food Allergy (OUTMATCH) trial, which led to the approval of omalizumab. The setting comprised 10 academic centers across the US. Included in this analysis were individuals aged 1 to 55 years with an allergy to peanuts and at least 2 other foods (milk, eggs, wheat, cashews, hazelnuts, walnuts). Eligibility was based on oral food challenge thresholds, requiring dose-limiting symptoms to cumulative doses of 144 mg or less of protein for peanuts and 444 mg or less for nonpeanut allergens. Data were analyzed from October 2024 to February 2026. Participants were randomized to receive MOIT with placebo omalizumab or omalizumab with placebo MOIT. All received 16 weeks of open-label omalizumab; at week 8, active or placebo MOIT was initiated and escalated to goal doses of 1000 mg per food. At week 16, participants transitioned to blinded omalizumab or placebo injections for 44 weeks. The primary end point was cumulative tolerated dose (CTD) of 4044 mg or greater for all 3 foods. Predefined secondary end points included CTDs of 1044, 2044, 4044, 6044, or 8044 mg for 1, 2, or all 3 foods. A total of 117 participants (median [IQR] age, 7 [1-29] years; 64 male [55%]) were randomized to receive active MOIT (n = 58) or active omalizumab (n = 59). A total of 30 participants (51%) receiving active MOIT and 51 (88%) receiving active omalizumab completed the study. In the intention-to-treat (ITT) analysis, omalizumab was superior to MOIT (21 of 58 [36%] vs 11 of 59 [19%]; odds ratio, 2.6; 95% CI, 1.1-6.3; P = .03), with no differences in per-protocol analyses. Omalizumab superiority for CTDs of 4044 mg or greater was also demonstrated for 2 or more foods and for several individual foods. More participants taking active MOIT experienced adverse events (serious adverse events in 18 of 59 [31%] vs 0%; events leading to discontinuation in 13 of 59 [22%] vs 0%; events treated with epinephrine (22 of 59 [37%] vs 4 of 58 [7%]). Although the ITT analysis found a higher rate of treatment success in those receiving omalizumab compared with MOIT, results suggest that the difference was largely driven by the high rate of study discontinuation in the participants treated with MOIT, mostly related to adverse events.

PMID 42507431
阅读全文 →
PubMedJournal of fungi (Basel, Switzerland)2026-07-27

Enhanced Production and Profiling of Ganoderic Acids in Ganoderma lucidum Mycelia via Two-Stage Cultivation and GNPS-Guided Metabolomics.

Tsao Chieh-Hsi CH, Tsai Hsin-Ya HY, Cheng Kai-Wen KW, Chen Guan-Yuan GY et al.

Ganoderic acids (GAs) are bioactive lanostane-type triterpenoids produced by Ganoderma lucidum that accumulate predominantly in fruiting bodies, whose long cultivation period limits their practical production. Using Global Natural Products Social Molecular Networking (GNPS), we identified G. lucidum TM701, which accumulated 99 GA derivatives in mycelia and exhibited higher triterpenoid levels and greater chemical diversity than the commercial strain BCRC 36203. Four abundant GAs (GA-Mb/Mc, GA-S/Mf, GA-T, and GA-R) were selected as marker compounds for monitoring GA production. A modified two-stage cultivation strategy, combining submerged inoculum preparation with nutrient optimization during static cultivation, increased GA production to 1396 mg L-1 GAs in potato dextrose broth supplemented with 2% glucose. Heat treatment revealed interconversion among GA-Mb/Mc, GA-Mh, and GA-P/Q, indicating a dehydration-driven stabilization of conjugated diene structures. G. lucidum TM701 mycelia not only provide a platform for triterpenoid production, but also serve as a promising model for elucidating GA biosynthesis and investigating their thermal transformation.

PMID 42506261
阅读全文 →
PubMedExpert review of vaccines2026-07-27

Adapted XBB.1.5 vaccine effectiveness against severe COVID-19 outcomes among immunocompromised persons in 2023-24 in six European countries: a VEBIS-EHR network study.

Blake Alexandre A, Humphreys James J, Olson Kate K, Braeye Toon T et al.

We estimated the XBB.1.5 vaccine effectiveness (VE) against COVID-19 hospitalization and death in Belgium, Denmark, Italy, Portugal, Spain (Navarre), and Sweden following the 2023-24 fall vaccination campaign among immunocompromised persons (ICPs). We conducted a multi-country retrospective cohort study using electronic health records. Study sites identified ICPs aged ≥18 years through a common set of immunocompromising conditions and follow-up started the first day of the 2023 vaccination campaign until 12 months later. VE was calculated by time since vaccination (14-59, 60-119, 120-179, 180-365 days after vaccination) for ICPs by pooling study site level confounder adjusted hazard ratios (aHR) of vaccination, estimated with Cox proportional hazards regression models, using a random effect meta-analysis with VE = 100 × (1-pooled aHR). The XBB.1.5 VE was 52% (95% confidence interval (CI): 41 to 60) and 75% (95%CI: 60 to 84) against hospitalization and death, respectively, 14-59 days after vaccination, and VE decreased with time since vaccination with no remaining protection at 180-365 days after vaccination. Adapted XBB.1.5 vaccine provided moderate protection within 120 days after vaccination against severe COVID-19 outcomes among ICPs aged ≥18 years during a period with BA.2.86/JN.1 replacing the XBB.1.5 variant.

PMID 42504085
阅读全文 →
PubMedAsia-Pacific journal of ophthalmology (Philadelphia, Pa.)2026-07-27

Three-year outcomes of phacogoniotomy versus phacotrabeculectomy for advanced primary angle-closure glaucoma with cataract: A randomized controlled trial.

Lin Fengbin F, Song Yunhe Y, Zhang Hengli H, Fan Sujie S et al.

To evaluate the 3-year efficacy and safety of phacogoniotomy versus phacotrabeculectomy for advanced primary angle-closure glaucoma (PACG) with cataract. Multicenter, randomized controlled, open-label, non-inferiority trial. Patients were randomized 1:1 to undergo either phacogoniotomy (65 eyes) or phacotrabeculectomy (59 eyes). Three years retention was 92.3% (60/65) and 83.1% (49/59) for each group, respectively. Primary outcome was 3-year intraocular pressure (IOP) reduction (noninferiority margin: 4mmHg). Secondary outcomes included surgical success, complications, hypotensive medications used; additional outcomes were changes in visual acuity (BCVA), VF, and corneal endothelial cell density (ECD). At 3 years, phacogoniotomy reduced mean IOP from 40.2 (10.3) to 14.1 (2.4) mmHg (-26.1 [10.4] mmHg reduction); phacotrabeculectomy, from 39.7 (9.3) to 14.4 (2.5) mmHg (-25.3 [9.2] mmHg reduction). Adjusted between-group difference in IOP change was -0.37mmHg (95% CI, -1.32 to 0.58mmHg; P = 0.44), meeting noninferiority. Complete (78.3% vs 89.8%; P = 0.13) and qualified (90.0% vs 91.8%; P > 0.999) success rates were comparable. Hypotensive medications declined in both groups (phacogoniotomy: 2.1 [1.2] to 0.2 [0.6]; phacotrabeculectomy: 2.1 [1.3] to 0.0 [0.2]; P = 0.06 for 3-year difference). BCVA improvements (0.1 vs 0.0 logMAR; P = 0.49), VF stability (MD difference:1.42dB, P = 0.26; PSD difference: 0.22dB, P = 0.75), and ECD loss (difference: 2%; P = 0.53) were similar. No new complications occurred in extended follow-up. At 3 years, phacogoniotomy remained non-inferior to phacotrabeculectomy in IOP reduction for advanced PACG with cataract.

PMID 42503334
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多MF-59